Health Headlines: FDA Greenlights Cancer Therapy, Leadership Shakeup at CVS, and Global Health Insights

The FDA approved Astellas' gastric cancer therapy. CVS Health CEO Karen Lynch steps down amid shareholder pressure, with David Joyner taking over. A Tennessee court blocked aspects of the abortion ban. WHO suggests front-label nutrition info for processed foods. The Mpox vaccine rollout in Congo lags behind schedule.

The U.S. FDA has approved a new Astellas therapy for treating gastric cancer, specifically for cases beginning at the gastroesophageal junction. This approval incorporates a combination with chemotherapy to enhance patient outcomes.

In corporate news, CVS Health's CEO Karen Lynch is stepping down after nearly four years in response to investor demands for improved business performance. Lynch will be succeeded by David Joyner amidst concerns over the company's stagnant stock price and a revised financial outlook.

Globally, the World Health Organization advocates for visibly placed nutritional information on food packaging. Additionally, Congo's vaccination effort against Mpox is progressing slower than anticipated, further complicating public health responses in affected regions.

(With inputs from agencies.)